CheckMyRecalls

Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for…

Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable Suspension

Published
13 May 2026
Units affected
2,200 kits
Agency
FDA
Country
United States

The hazard

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1¿ 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Diluent Label: 0480-9263-21.

Brand / company
Teva Pharmaceuticals USA, Inc
Codes / lots
Lot: 45011002, Exp. 03/31/2027
Distribution
Nationwide in the USA
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 13 May 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.